Even more powerful!

Recent popular reports from Yimike ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ The 2021 American Society of Hematology (ASH) annual meeting is about to open.
What are the new developments in the treatment of acute myeloid leukemia (AML) this year? Yimai Meng broke the news, click on the picture, and sign up to attend the conference on November 16, 2021/eMedClub News/--US private equity giant Blackstone Group recently announced that it will inject up to US$250 million in British biotechnology company Autolus Therapeutics.
Fund the final phase of the development of a new treatment for severe leukemia
.

In this investment, up to US$150 million will be used to develop and commercialize obecabtagene autoleucel (Obe-cel), a targeted CD19 CAR-T cell therapy for the treatment of acute lymphoblastic leukemia
.

According to the terms of the agreement, the Blackstone Group will provide product financing support of US$150 million for the development and commercialization of Obe-cel, of which US$50 million will be paid when the transaction is completed, and the rest will be paid based on the development and regulatory milestones reached
.

In return, Blackstone's life science department will share the royalties of the drug after the drug is marketed
.

The company also purchased Autolus' American Depositary Shares (ADS) valued at US$100 million through private placement, thereby obtaining the right to nominate members of the Autolus board of directors
.

"Serial killer" Obe-celObe-cel is a CAR-T therapy that targets CD19 and has a fast target binding and dissociation rate.
It can reduce toxicity, reduce the possibility of T cell failure, and improve programmed T cell targeting The ability of cancer cells
.

Obe-cel can effectively identify cancer cells, and inject cytotoxic protein to initiate the cell self-destruction process, quickly dissociate, and then combine with the next cancer cell
.

This process is also called "serial killer"
.

▲ The engineered T cells recognize and destroy malignant cells (picture source: Autolus official website) Recommended reading: 100% complete remission rate! "Serial killer" CD19 CAR-T announces early clinical dataYi Mai Meng broke the news "Serial killer" CD19 CAR-T has entered the British Drug Administration to innovate licenses and access channelsYi Mai Meng broke the news and was recognized again! The "serial killer" CD19 CAR-T has been certified as a breakthrough innovative drug by the British Food and Drug AdministrationYimai Meng broke the news.
At present, Obe-cel is in its phase IB/2 clinical trial for its overall response rate, response duration, and MRD negative CR rate And to evaluate the safety of treating adult acute lymphoblastic leukemia (ALL), also known as the FELIX clinical trial
.

Recommended reading: Phase 1 clinical data is encouraging! "Serial killer" CD19 CAR-T reappears sharpnessDr.
Kerry Christian Itin, CEO of Autolus, commented in a statement: "We welcome Blackstone Life Sciences to join our action to change patients with leukemia and lymphoma.
the prospect
.

Blackstone's investment and expertise will support Obe-cel commercial development and preparation, and the project has a strong financial base
.

we will interpret potentially pivotal FELIX clinical trials during 2022
.

"references : 1.
https://